1. Articles from ncbi.nlm.nih.gov

  2. 1-24 of 1410 1 2 3 4 ... 57 58 59 »
    1. Sequential actions of immune effector cells induced by viral activation of dendritic cells to eliminate murine neuroblastoma.

      Sequential actions of immune effector cells induced by viral activation of dendritic cells to eliminate murine neuroblastoma.

      J Pediatr Surg. 2017 Aug 26;:

      Authors: Kawakubo N, Tanaka S, Kinoshita Y, Tajiri T, Yonemitsu Y, Taguchi T

      Abstract PURPOSE: In preclinical trails, we reported the antitumor effect of dendritic cells activated with Sendai virus (rSeV/DC) combined with γ-irradiation against neuroblastoma.

      Read Full Article
    2. GPC2 May Be an Immunotherapeutic Target in High-Risk Neuroblastoma.

      GPC2 May Be an Immunotherapeutic Target in High-Risk Neuroblastoma.

      Cancer Discov. 2017 Sep 22;:

      Authors:

      Abstract A GPC2-targeting antibody-drug conjugate promotes tumor regression in a high-risk neuroblastoma PDX.

      PMID: 28939655 [PubMed - as supplied by publisher]

      Read Full Article
      Mentions: Antibody
    3. A pilot trial of humanized anti-GD2 monoclonal antibody (hu14.18K322A) with chemotherapy and natural killer cells in children with recurrent/refractory neuroblastoma.

      A pilot trial of humanized anti-GD2 monoclonal antibody (hu14.18K322A) with chemotherapy and natural killer cells in children with recurrent/refractory neuroblastoma.

      Clin Cancer Res. 2017 Sep 22;:

      Authors: Federico SM, McCarville MB, Shulkin BL, Sondel PM, Hank JA, Hutson P, Meagher M, Shafer A, Ng CY, Leung W, Janssen WE, Wu J, Mao S, Brennan RC, Santana VM, Pappo A, Furman WL

      Read Full Article
    4. Chronic radiation exposure of neuroblastoma cells reduces nMYC copy number.

      Chronic radiation exposure of neuroblastoma cells reduces nMYC copy number.

      Oncol Lett. 2017 Sep;14(3):3363-3370

      Authors: Gnanamony M, Antony R, Fernández KS, Jaime L, Lin J, Joseph PA, Gondi CS

      Abstract Neuroblastoma accounts for >15% of cancer-associated mortalities of children in the USA. Despite aggressive treatment regimens, the long-term survival for these children remains <40%.

      Read Full Article
      Mentions: Treatment
    5. Anticancer efficacy of p-dodecylaminophenol against high-risk and refractory neuroblastoma cells in vitro and in vivo.

      Anticancer efficacy of p-dodecylaminophenol against high-risk and refractory neuroblastoma cells in vitro and in vivo.

      Bioorg Med Chem Lett. 2017 Sep 09;:

      Authors: Takahashi N, Koyama S, Hasegawa S, Yamasaki M, Imai M

      Abstract Neuroblastoma is an aggressive and drug-resistant refractory cancer.

      Read Full Article
      Mentions: Refractory
    6. Manipulation of variables in local controlled release vincristine treatment in neuroblastoma.

      Manipulation of variables in local controlled release vincristine treatment in neuroblastoma.

      J Pediatr Surg. 2017 Sep 04;:

      Authors: Coburn JM, Harris J, Cunningham R, Zeki J, Kaplan DL, Chiu B

      Abstract INTRODUCTION: Local drug delivery minimizes systemic toxicity while delivering high-dose chemotherapy for neuroblastoma patients. We hypothesized that varying burst and maintenance dosing of implanted silk platforms would improve survival.

      Read Full Article
    7. Common variants in MMP20 at 11q22.2 predispose to 11q deletion and neuroblastoma risk.

      Common variants in MMP20 at 11q22.2 predispose to 11q deletion and neuroblastoma risk.

      Nat Commun. 2017 Sep 18;8(1):569

      Authors: Chang X, Zhao Y, Hou C, Glessner J, McDaniel L, Diamond MA, Thomas K, Li J, Wei Z, Liu Y, Guo Y, Mentch FD, Qiu H, Kim C, Evans P, Vaksman Z, Diskin SJ, Attiyeh EF, Sleiman P, Maris JM, Hakonarson H

      Read Full Article
      Mentions: MYCN
    8. Patient-derived xenografts as preclinical neuroblastoma models.

      Patient-derived xenografts as preclinical neuroblastoma models.

      Cell Tissue Res. 2017 Sep 19;:

      Authors: Braekeveldt N, Bexell D

      Abstract The prognosis for children with high-risk neuroblastoma is often poor and survivors can suffer from severe side effects. Predictive preclinical models and novel therapeutic strategies for high-risk disease are therefore a clinical imperative.

      Read Full Article
      Mentions: Side Effects
    9. Acquired Intermittent Pediatric Horner Syndrome due to Neuroblastoma.

      Acquired Intermittent Pediatric Horner Syndrome due to Neuroblastoma.

      Ophthal Plast Reconstr Surg. 2017 Sep 13;:

      Authors: Cohen LM, Elliott A, Freitag SK

      Abstract A 3-month-old male developed intermittent left upper eyelid ptosis at the age of 1 month that was gradually increasing in frequency and duration. Examination revealed anisocoria and left upper and lower eyelid ptosis, consistent with a left Horner syndrome.

      Read Full Article
      Mentions: Imaging
    10. Palmitic acid stimulates energy metabolism and inhibits insulin/PI3K/AKT signaling in differentiated human neuroblastoma cells: The role of mTOR activation and mitochondrial ROS production.

      Palmitic acid stimulates energy metabolism and inhibits insulin/PI3K/AKT signaling in differentiated human neuroblastoma cells: The role of mTOR activation and mitochondrial ROS production.

      Neurochem Int. 2017 Sep 15;:

      Authors: Calvo-Ochoa E, Sánchez-Alegría K, Gómez-Inclán C, Ferrera P, Arias C

      Read Full Article
    11. Composite iron oxide-Prussian blue nanoparticles for magnetically guided T1-weighted magnetic resonance imaging and photothermal therapy of tumors.

      Composite iron oxide-Prussian blue nanoparticles for magnetically guided T1-weighted magnetic resonance imaging and photothermal therapy of tumors.

      Int J Nanomedicine. 2017;12:6413-6424

      Authors: Kale SS, Burga RA, Sweeney EE, Zun Z, Sze RW, Tuesca A, Subramony JA, Fernandes R

      Read Full Article
    12. Neuroblastoma cells undergo transcriptomic alterations upon dissemination into the bone marrow and subsequent tumor progression.

      Neuroblastoma cells undergo transcriptomic alterations upon dissemination into the bone marrow and subsequent tumor progression.

      Int J Cancer. 2017 Sep 16;:

      Authors: Rifatbegovic F, Frech C, Abbasi MR, Taschner-Mandl S, Weiss T, Schmidt WM, Schmidt I, Ladenstein R, Ambros IM, Ambros PF

      Read Full Article
      Mentions: Bone Marrow
    13. Investigational drugs in phase II clinical trials for the treatment of neuroblastoma.

      Investigational drugs in phase II clinical trials for the treatment of neuroblastoma.

      Expert Opin Investig Drugs. 2017 Sep 14;:

      Authors: Amoroso L, Haupt R, Garaventa A, Ponzoni M

      Abstract INTRODUCTION: Neuroblastoma (NB) is an embryonal tumor originating from undifferentiated neural crest cell, highly heterogeneous ranging from spontaneous regression to progression despite multimodal treatments.

      Read Full Article
      Mentions: Treatment
    14. Therapy-related Acute Leukemia With Mixed Phenotype and Novel t(1: 6)(q25;p23) After Treatment for High-risk Neuroblastoma.

      Therapy-related Acute Leukemia With Mixed Phenotype and Novel t(1: 6)(q25;p23) After Treatment for High-risk Neuroblastoma.

      J Pediatr Hematol Oncol. 2017 Sep 08;:

      Authors: Whittle SB, Punia JN, López-Terrada D, Gaikwad A, Hampton OA, Heczey A

      Abstract Neuroblastoma is the most common extracranial malignancy of childhood.

      Read Full Article
      Mentions: Treatment
    15. Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma.

      Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma.

      Cancer Cell. 2017 Sep 11;32(3):271-273

      Authors: Malone CF, Stegmaier K

      Abstract In this issue of Cancer Cell, Bosse et al. report GPC2 as a therapeutic target in neuroblastoma. They show that GPC2 is selectively expressed on the cell surface of neuroblastoma and is a dependency in this disease. Moreover, they demonstrate the therapeutic potential of an antibody-drug conjugate targeting GPC2.

      Read Full Article
      Mentions: Antibody
    16. When LMO1 Meets MYCN, Neuroblastoma Is Metastatic.

      When LMO1 Meets MYCN, Neuroblastoma Is Metastatic.

      Cancer Cell. 2017 Sep 11;32(3):273-275

      Authors: Liu Z, Thiele CJ

      Abstract LMO1 is a high-risk neuroblastoma susceptibility gene, but how LMO1 cooperates with MYCN in neuroblastoma tumorigenesis is unclear. In this issue of Cancer Cell, Zhu et al. develop a novel zebrafish model that elucidates a mechanism by which LMO1 and MYCN synergistically initiate neuroblastoma and contribute to metastatic disease progression.

      Read Full Article
      Mentions: MYCN Tumorigenesis
    17. Validation of post-induction Curie scores in high risk neuroblastoma. A Children's Oncology Group (COG) and SIOPEN group report on SIOPEN/HR-NBL1.

      Validation of post-induction Curie scores in high risk neuroblastoma. A Children's Oncology Group (COG) and SIOPEN group report on SIOPEN/HR-NBL1.

      J Nucl Med. 2017 Sep 08;:

      Authors: Yanik GA, Parisi MT, Naranjo A, Nadel H, Gelfand MJ, Park JR, Ladenstein RL, Poetschger U, Boubaker A, Valteau-Couanet D, Lambert B, Castellani MR, Bar-Sever Z, Oudoux A, Kaminska A, Kreissman SG, Shulkin BL, Matthay KK

      Read Full Article
      Mentions: Staging SIOPEN COG
    18. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials.

      Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials.

      Cancer. 2017 Sep 08;:

      Authors: London WB, Bagatell R, Weigel BJ, Fox E, Guo D, Van Ryn C, Naranjo A, Park JR

      Read Full Article
      Mentions: COG Refractory MYCN
    19. Peripheral Blood Biomarkers Associated With Toxicity and Treatment Characteristics After (131)I- Metaiodobenzylguanidine Therapy in Patients With Neuroblastoma.

      Peripheral Blood Biomarkers Associated With Toxicity and Treatment Characteristics After (131)I- Metaiodobenzylguanidine Therapy in Patients With Neuroblastoma.

      Int J Radiat Oncol Biol Phys. 2017 Oct 01;99(2):468-475

      Authors: Campbell K, Karski EE, Olow A, Edmondson DA, Kohlgruber AC, Coleman M, Haas-Kogan DA, Matthay KK, DuBois SG

      Read Full Article
    20. Renal Function Outcomes of High-risk Neuroblastoma Patients Undergoing Radiation Therapy.

      Renal Function Outcomes of High-risk Neuroblastoma Patients Undergoing Radiation Therapy.

      Int J Radiat Oncol Biol Phys. 2017 Oct 01;99(2):486-493

      Authors: Beckham TH, Casey DL, LaQuaglia MP, Kushner BH, Modak S, Wolden SL

      Abstract PURPOSE: To analyze the renal function outcomes in patients undergoing radiation therapy for neuroblastoma.

      Read Full Article
    21. Prolonged Isotretinoin in Ultra High-Risk Neuroblastoma.

      Prolonged Isotretinoin in Ultra High-Risk Neuroblastoma.

      J Pediatr Hematol Oncol. 2017 Jan;39(1):e33-e35

      Authors: Cash T, Alazraki A, Qayed M, Katzenstein HM

      Abstract Patients with high-risk neuroblastoma remain a therapeutic challenge with significant numbers of patients failing to respond sufficiently to initial therapy. These patients with poor response to induction are considered as ultra high-risk and are in need of novel treatment strategies.

      Read Full Article
      Mentions: Treatment
    1-24 of 1410 1 2 3 4 ... 57 58 59 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video